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Background
Acute myeloid leukemias arise from a rare population of leukemic cells, known as leukemic stem cells, which initiate the disease and contribute to frequent relapses. Although the phenotype of these cells remains unclear in most patients, these cells are enriched within the CD34 + CD38
low/-compartment expressing the interleukin-3 alpha chain receptor, CD123. The aim of this study was to determine the prognostic value of the percentage of blasts with the CD34 + CD38 low/-
CD123
+ phenotype.
Design and Methods
The percentage of CD34 + CD38 low/-CD123 + cells in the blast population was determined at diagnosis using flow cytometry. One hundred and eleven patients under 65 years of age with de novo acute myeloid leukemia and treated with intensive chemotherapy were retrospectively included in the study. Correlations with complete response, disease-free survival and overall survival were evaluated with univariate and multivariate analyses. 
CD123
+ cells retained prognostic significance for both parameters after multivariate analysis.
Conclusions
The percentage of CD34 + CD38 low/-
CD123
+ leukemic cells at diagnosis was significantly correlated with response to treatment and survival. This prognostic marker might be easily adopted in clinical practice to rapidly identify patients at risk of treatment failure. 1,2 Currently, the combination of an anthracycline and cytarabine is still considered to be the gold standard induction therapy for younger patients with AML, resulting in complete remission rates of 50 to 75%. 3 However, relapses frequently occur and the 5-year overall survival rate is less than 40% even after high-dose chemotherapy and stem cell transplantation. 4 In recent years, the characterization of new molecular prognostic tools has led to a tailored therapeutic approach. This is particularly true for the most heterogeneous group of AML patients with a normal karyotype who account for 40% to 50% of the cases. Many molecular abnormalities in different genes, including FLT3, NPM1, RUNX1, CEPBA, IDH1/2, and WT1 mutations, have now been identified in this disease and have been reported to have a significant effect on the clinical outcome of such patients. 5 Relapses from AML are thought to originate from the outgrowth of a leukemic subpopulation with both selfrenewal and chemoresistance properties and that likely resides in particular niches of the bone marrow. 6, 7 This leukemic sub-population was initially characterized in sub-lethally irradiated non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice and leukemic stem cells were found to be enriched in the CD34 + CD38 low/-compartment. 8, 9 Taussig et al. revealed a bias in experimental conditions and demonstrated that the leukemic stem cell phenotype was more heterogeneous than previously thought. 10 Moreover it was recently demonstrated that although all immature AML subpopulations may contain leukemic stem cells in a different model of human AML cell transplantation in NOD/SCID/IL2rγ null mice, [11] [12] [13] 14 More importantly and regardless of their 'stemness' properties, it has been demonstrated both in vitro and in vivo that CD34 + CD38 low/-cells are significantly more resistant than the leukemic bulk population to classical chemotherapeutic agents. 13, 15 Previous studies have emphasized the correlation between the enrichment of the CD34 + or CD34 + CD38
low/-phenotype in AML or acute lymphoblastic leukemia cells at diagnosis and a high level of residual disease after treatment. [16] [17] [18] However, the prognostic value of the percentage of CD34 + CD38 low/-
+ cells in the blast population has not been specifically addressed in AML. In the present study it was found that a percentage of leukemic CD34 + CD38
low/-CD123 + cells greater than 1% was strongly correlated with decreases in both disease-free and overall survival in AML patients.
Design and methods
Patients
One hundred and eleven patients under 65 years old with de novo AML were included in the present study. Patients with a history of myelodysplastic syndrome or therapy-related AML were not included. All the patients were treated according to the LAM-2001, 19 
Flow cytometry
Blast cells were isolated from bone marrow aspirates that were collected at diagnosis and also at relapse from some patients, by Ficoll-Hypaque gradient density centrifugation. The experiments were done on fresh cells (in 15% of cases) or retrospectively on cells frozen with 10% dimethyl sulfoxide (Sigma-Aldrich, Saint Louis, MO, USA) (in 85% of the cases). We did not observe any differences in the staining pattern for five patients using frozen and fresh cells (Online Supplementary Figure S1 ). After thawing, a total of 5¥10 5 primary AML blast cells were stained with the following conjugated antibodies: CD38-PE, CD123-PC5, CD45-FITC and CD34-PC7, or isotypic controls of the corresponding fluorochromes in accordance with the manufacturer's instructions (Beckman-Coulter Inc., Brea, CA, USA). Isotypic controls were used to define the threshold for positive-staining cells. Patients with CD34 expression of less than 1% were not included given the fact that in most of these cases CD34 + cells are not malignant cells. 20 Analyses were performed on an FC 500 flow cytometer with CXP software (Beckman-Coulter Inc., Brea, CA, USA) or on an LSRII flow cytometer with BD FacsDiVa software (BD Biosciences, Franklin Lakes, NJ, USA) in two institutional hematology laboratories in Cochin Hospital (Paris, France) and in Toulouse (France). We analyzed 11 AML samples with the two flow cytometers to validate the reproducibility of the results (Online Supplementary Figure S1 ).
Statistics
Complete response and relapse rates were defined according to the Cheson criteria. 21 The best thresholds for continuous variables were calculated using receiver operating characteristic (ROC) curves. Pair-wise comparisons between patients' characteristics (covariates) were performed using the Mann-Whitney test or Kruskal-Wallis test for continuous variables and with the Fisher's exact test for categorical variables. A multivariable logistic model was used to analyze associations between presenting features and response to induction therapy. Overall survival and disease-free survival rates were measured from the date of diagnosis until death and from the date of complete remission until death or relapse, respectively. Patients alive in complete remission were censored at the time of last contact. Overall and disease-free survival rates were estimated by the Kaplan-Meier method and compared using the log-rank test. Hazard ratios are given with 95% confidence intervals (95% CI). All calculations were performed using GraphPad Prism software, version 5.0 (GraphPad Software Inc., La Jolla, CA, USA). Survival-time data (disease-free survival and overall survival) and covariates (age, leukocyte count, karyotype, NPM-1 and FLT3 mutations and percentage of CD34 + CD38 low/-CD123 + cells) were analyzed using the method of backward Cox proportional hazards regression. (Table 3) . Moreover, a percentage of CD34 + CD38
low/-CD123 + cells of over 1% retained adverse prognostic significance for disease-free survival by multivariate analysis (95% CI, 0.13-0.55; P=0.00027). Age over 50 years, and an FLT3-ITD mutation were found to be significantly associated with decreased overall survival, while leukocyte count and the percentage of CD123 + cells had no impact on overall survival (Table 4) . In contrast, a CD34 + CD38 low/-CD123 + percentage of over 1% was found to be significantly associated with decreased overall survival (Figure 2) . Moreover, having more than 1% of CD34 + CD38 low/-CD123 + cells retained an adverse prognostic value within the intermediate and favorable karyotype groups (Figure 2 ) but had no impact on the prognosis in the unfavorable karyotype group (Online Supplementary Figure S2) . Remarkably, a percentage of CD34 + CD38 low/-CD123 + cells of over 1% remained highly predictive for reduced overall survival when submitted to multivariate analysis (95% CI, 0.11-0.49; P=0.00011, Table 4 ). A favorable karyotype and NPM1 mutation were also significantly associated with a better overall survival by multivariate analysis. 
Discussion
AML is a clinically and biologically heterogeneous disease for which prognostic factors have become increasingly important for the choice of the appropriate therapy. Although cytogenetic findings at diagnosis provide vital prognostic information, important subgroup definitions are now based on the mutational status of genes such as FLT3, NPM-1, CEBPA, IDH1/2 and c-KIT, which are among the most relevant for this disease. 23 However, new prognostic tools based on biological analyses need to be developed. They must be accurate and easily available in a clinical setting. Flow cytometry is one such interesting technique as results can be obtained quickly (within a day) and with a high degree of sensitivity.
Guzman et al. showed that the leukemic cell subpopulation bearing the CD34 + CD38 low/-
CD123
+ phenotype was in a quiescent state and highly resistant to both idarubicin and cytarabine in vitro. 24 Moreover, Ishikawa et al. elegantly demonstrated that, when injected into newborn NOD/SCID/IL2rγ null mice, this subpopulation resides preferentially in the bone-marrow endosteal region where it is protected from cytarabine-induced apoptosis. 15 These results strongly argue that an enrichment of chemoresistant cells, from which relapses might arise, occurs within the CD34 
+ cells to chemotherapy using oxidative stress-inducing agents, inhibitors of NF-kB or PI3 kinase, or mobilizing agents from their niches with growth factors.
However, no study had assessed the clinical relevance of the percentage of CD34 + CD38 low/-CD123 + cells in AML patients treated with intensive chemotherapy. We show that this leukemic subpopulation is not so rare in patients as we found up to 67% of CD34 + CD38 low/-CD123 + cells in the bulk of blasts. Flow cytometry is the best technology for detecting subpopulations as it can easily discriminate less than 0.01% of cells. 25 Accordingly, our thresholds, which were a hundred times higher than the accuracy of the technology, can be easily set in daily practice, especially as the percentages of CD34 + CD38 low/-CD123 + leukemic cells ranged from 0.01% to 67%. Although the results of our present study need to be confirmed in a prospective manner and in a larger cohort, our data do show that a high level of CD34 + CD38
low/-CD123 + cells at diagnosis is quite predictive of an increased risk of induction failure. This finding may have important implications for early therapeutic intervention because this phenotype can be routinely established within 1 day. The results of cytogenetic and molecular analyses are usually obtained in the month after starting induction chemotherapy and are, therefore, helpful to physicians only at the time of remission to determine the type of consolidation to use (e.g. allogeneic transplantation or not). Hence, the assessment of the level of CD34 + CD38 low/-CD123 + cells at diagnosis could help clinicians to quickly identify patients at risk of induction failure and thereby improve the response rate by using different therapeutic strategies. Moreover, a percentage of CD34 + CD38 low/-CD123 + cells of more than 1% is strongly associated with early relapses as shown by the diseasefree survival curves suggesting that residual disease is likely to be high in these patients. A recent study by low/-population in a cohort of 17 children. 18 In our study we found that the CD34 + CD38 low/-CD123 + phenotype was more accurate at identifying patients with a worse prognosis (Online Supplementary Figure S3) .
Finally, a number of recent studies have emphasized CD123 expression as a valuable therapeutic target in AML and several phase I studies assessing anti-CD123 monoclonal antibodies targeting leukemic stem cells in AML are ongoing. Jin et al. used an anti-CD123 neutralizing antibody, 7G3, in a NOD/SCID mice model of human AML and showed a reduction of the AML burden in mice with pre-established disease and impaired secondary transplantation. 26 Fey et al. also showed the in vitro anti-leukemic activity of Fv fragment antibodies directed against CD123, CD33 and CD16 in AML. 27, 28 These anti-CD123 targeted therapies should be tested in AML patients, and particularly in cases demonstrating a high CD34 Overall, our results demonstrate the negative prognostic significance of high levels of CD34 + CD38 low/-CD123 + leukemic cells detected by flow cytometry at diagnosis in AML patients treated with intensive chemotherapy. These findings will now be pursued prospectively in a larger cohort of patients and, if confirmed, the detection of this cell subpopulation within the leukemic bulk could become a cornerstone of risk-stratified AML clinical trials in the near future.
Authorship and Disclosures
The 
